Clinical Trial Update: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

A Phase III study of YL201 for recurrent or metastatic Nasopharyngeal carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• YL201

Snippet

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: RECRUITING